Supplementary Material for Endoscopic Duodenal Mucosal Resurfacing for the Treatment of Type 2 Diabetes

Type 2 diabetes is a pandemic disease with an incidence that<br>has risen steadily over recent decades. Experimental evidence<br>in animals has demonstrated that intestinal bypass<br>surgery of the upper small intestine, particularly the duodenum,<br>has an important role in glucose homoeostasis. Furthermore,<br>Roux-en-Y bypass performed as bariatric surgery<br>has shown to correct hyperglycaemia from the first postoperative<br>days in obese diabetic patients. Therefore, on the basis<br>of these considerations, duodenal mucosal resurfacing<br>was studied in type 2 diabetes patients as a minimally invasive<br>procedure that could offer an alternative treatment for<br>these patients. Further studies, and particularly large controlled<br>trials, are needed to determine the place of this procedure<br>in the treatment of type 2 diabetes as well as other<br>metabolic diseases such as non-alcoholic fatty liver disease/<br>non-alcoholic steatohepatitis.